Factors that predict pursuing sinus surgery in the era of highly effective modulator therapy.
chronic rhinosinusitis
cystic fibrosis
endoscopic sinus surgery
highly effective modulator therapy
patient symptoms
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
19 Sep 2023
19 Sep 2023
Historique:
revised:
19
07
2023
received:
30
05
2023
accepted:
08
09
2023
medline:
19
9
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
aheadofprint
Résumé
Comorbid chronic rhinosinusitis (CRS) remains unresolved for many people with cystic fibrosis (PwCF). While highly effective modulator therapy improves quality-of-life and symptom severity, the impact of this intervention and other factors associated with pursuing endoscopic sinus surgery (ESS) remains understudied. Adult PwCF + CRS were enrolled into a prospective, observational, multi-institutional study. Participants completed validated outcome measures to evaluate respiratory symptom severity, depression, headache, and sleep quality, as well as nasal endoscopy, sinus computed tomography (CT), and olfactory testing. Bivariate comparisons and regression modeling evaluated treatment cofactors, disease characteristics, and outcome measures associated with pursuing ESS. Sixty PwCF were analyzed, including 24 (40%) who elected ESS. Pursuing ESS was associated with worse SinoNasal Outcome Test (SNOT-22) total, rhinologic, psychological, and sleep dysfunction domain scores; worse Patient Health Questionnaire-9-Revised depression scores; worse Pittsburgh Sleep Quality Index total scores; worse weight, role, emotion, and eating domain scores on the Cystic Fibrosis Questionnaire-Revised; more severe disease on nasal endoscopy; and lack of modulator therapy (all p < 0.050). Multivariable regression identified that worse SNOT-22 total score was associated with electing ESS (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.02-1.16, p = 0.015) and elexacaftor/tezacaftor/ivacaftor (ETI) treatment (OR 0.04, 95% CI 0.004-0.34, p = 0.004) was associated with pursing medical therapy. Worse sinonasal symptom burden, lack of ETI treatment, sleep quality, depression, and nasal endoscopy scores were associated with electing ESS, while lung disease severity and sinus CT scores were not. ETI use was associated with lower odds of pursuing ESS independent of sinonasal symptom burden.
Sections du résumé
BACKGROUND
BACKGROUND
Comorbid chronic rhinosinusitis (CRS) remains unresolved for many people with cystic fibrosis (PwCF). While highly effective modulator therapy improves quality-of-life and symptom severity, the impact of this intervention and other factors associated with pursuing endoscopic sinus surgery (ESS) remains understudied.
METHODS
METHODS
Adult PwCF + CRS were enrolled into a prospective, observational, multi-institutional study. Participants completed validated outcome measures to evaluate respiratory symptom severity, depression, headache, and sleep quality, as well as nasal endoscopy, sinus computed tomography (CT), and olfactory testing. Bivariate comparisons and regression modeling evaluated treatment cofactors, disease characteristics, and outcome measures associated with pursuing ESS.
RESULTS
RESULTS
Sixty PwCF were analyzed, including 24 (40%) who elected ESS. Pursuing ESS was associated with worse SinoNasal Outcome Test (SNOT-22) total, rhinologic, psychological, and sleep dysfunction domain scores; worse Patient Health Questionnaire-9-Revised depression scores; worse Pittsburgh Sleep Quality Index total scores; worse weight, role, emotion, and eating domain scores on the Cystic Fibrosis Questionnaire-Revised; more severe disease on nasal endoscopy; and lack of modulator therapy (all p < 0.050). Multivariable regression identified that worse SNOT-22 total score was associated with electing ESS (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.02-1.16, p = 0.015) and elexacaftor/tezacaftor/ivacaftor (ETI) treatment (OR 0.04, 95% CI 0.004-0.34, p = 0.004) was associated with pursing medical therapy.
CONCLUSIONS
CONCLUSIONS
Worse sinonasal symptom burden, lack of ETI treatment, sleep quality, depression, and nasal endoscopy scores were associated with electing ESS, while lung disease severity and sinus CT scores were not. ETI use was associated with lower odds of pursuing ESS independent of sinonasal symptom burden.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cystic Fibrosis Foundation
ID : BESWIC20A0
Informations de copyright
© 2023 ARS-AAOA, LLC.
Références
Berkhout MC, van Rooden CJ, Rijntjes E, Fokkens WJ, el Bouazzaoui LH, Heijerman HG. Sinonasal manifestations of cystic fibrosis: a correlation between genotype and phenotype? J Cyst Fibros. 2014;13(4):442-448. doi:10.1016/j.jcf.2013.10.011
Gudis DA, Schlosser RJ. The Unified Airway: Rhinologic Disease and Respiratory Disorders. Springer International Publishing; 2020.
Zemke AC, Nouraie SM, Moore J, et al. Clinical predictors of cystic fibrosis chronic rhinosinusitis severity. Int Forum Allergy Rhinol. 2019;9(7):759-765. doi:10.1002/alr.22332
Campbell AP, Phillips KM, Hoehle LP, et al. Depression symptoms and lost productivity in chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2017;118(3):286-289. doi:10.1016/j.anai.2016.12.012
Habib AR, Buxton JA, Singer J, Wilcox PG, Javer AR, Quon BS. Association between chronic rhinosinusitis and health-related quality of life in adults with cystic fibrosis. Ann Am Thorac Soc. 2015;12(8):1163-1169. doi:10.1513/AnnalsATS.201504-191OC
Pandrangi VC, Mace JC, Kim JH, et al. Work productivity and activity impairment in patients with chronic rhinosinusitis undergoing endoscopic sinus surgery-a prospective, multi-institutional study. Int Forum Allergy Rhinol. 2023;13(3):216-229. doi:10.1002/alr.23070
Kimple AJ, Senior BA, Naureckas ET, et al. Cystic fibrosis foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol. 2022;12(9):1089-1103. doi:10.1002/alr.22974
Spielman DB, Beswick DM, Kimple AJ, et al. The management of cystic fibrosis chronic rhinosinusitis: an evidenced-based review with recommendations. Int Forum Allergy Rhinol. 2021;12:1148-1183. doi:10.1002/alr.22953
Smith KA, Gill AS, Beswick DM, et al. Cystic fibrosis increases long-term revision rates of endoscopic sinus surgery in patients with comorbid chronic rhinosinusitis. Am J Rhinol Allergy. 2022;36(2):222-228. doi:10.1177/19458924211046719
Soler ZM, Rudmik L, Hwang PH, Mace JC, Schlosser RJ, Smith TL. Patient-centered decision making in the treatment of chronic rhinosinusitis. Laryngoscope. 2013;123(10):2341-2346. doi:10.1002/lary.24027
Beswick DM, Humphries SM, Balkissoon CD, et al. Impact of cystic fibrosis transmembrane conductance regulator therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient-reported outcomes. Ann Am Thorac Soc. 2022;19(1):12-19. doi:10.1513/AnnalsATS.202101-057OC
DiMango E, Overdevest J, Keating C, Francis SF, Dansky D, Gudis D. Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis. J Cyst Fibros. 2021;20(3):460-463. doi:10.1016/j.jcf.2020.07.002
Stapleton AL, Kimple AJ, Goralski JL, et al. Elexacaftor-tezacaftor-ivacaftor improves sinonasal outcomes in cystic fibrosis. J Cyst Fibros. 2022;21(5):792-799. doi:10.1016/j.jcf.2022.03.002
Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739. doi:10.1002/alr.22741
Rosenfeld RM. Clinical practice guideline on adult sinusitis. Otolaryngol Head Neck Surg. 2007;137(3):365-377. doi:10.1016/j.otohns.2007.07.021
Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998;6(2):65-74. doi:10.1080/105294199277860
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
Beswick DM, Humphries SM, Balkissoon CD, et al. Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy. J Cyst Fibros. 2022;21(2):e141-e147. doi:10.1016/j.jcf.2021.09.014
Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22(4):607-614. doi:10.1016/j.jcf.2023.02.004
Alt JA, Smith TL, Mace JC, Soler ZM. Sleep quality and disease severity in patients with chronic rhinosinusitis. Laryngoscope. 2013;123(10):2364-2370. doi:10.1002/lary.24040
Jankelowitz L, Reid KJ, Wolfe L, Cullina J, Zee PC, Jain M. Cystic fibrosis patients have poor sleep quality despite normal sleep latency and efficiency. Chest. 2005;127(5):1593-1599. doi:10.1378/chest.127.5.1593
Milross MA, Piper AJ, Norman M, et al. Subjective sleep quality in cystic fibrosis. Sleep Med. 2002;3(3):205-212. doi:10.1016/s1389-9457(01)00157-5
Sarraf P, Azizi S, Moghaddasi AN, Sahraian MA, Tafakhori A, Ghajarzadeh M. Relationship between sleep quality and quality of life in patients with multiple sclerosis. Int J Prev Med. 2014;5(12):1582-1586.
Alt JA, Smith TL, Schlosser RJ, Mace JC, Soler ZM. Sleep and quality of life improvements after endoscopic sinus surgery in patients with chronic rhinosinusitis. Int Forum Allergy Rhinol. 2014;4(9):693-701. doi:10.1002/alr.21364
Sukato DC, Abramowitz JM, Boruk M, Goldstein NA, Rosenfeld RM. Endoscopic sinus surgery improves sleep quality in chronic rhinosinusitis: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2018;158(2):249-256. doi:10.1177/0194599817737977
Quittner AL, Goldbeck L, Abbott J, et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014;69(12):1090-1097. doi:10.1136/thoraxjnl-2014-205983
Schlosser RJ, Gage SE, Kohli P, Soler ZM. Burden of illness: a systematic review of depression in chronic rhinosinusitis. Am J Rhinol Allergy. 2016;30(4):250-256. doi:10.2500/ajra.2016.30.4343
DeConde AS, Mace JC, Bodner T, et al. SNOT-22 quality of life domains differentially predict treatment modality selection in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2014;4(12):972-979. doi:10.1002/alr.21408
Mace J, Michael YL, Carlson NE, Litvack JR, Smith TL. Effects of depression on quality of life improvement after endoscopic sinus surgery. Laryngoscope. 2008;118(3):528-534. doi:10.1097/MLG.0b013e31815d74bb
Mattos JL, Schlosser RJ, Storck KA, Soler ZM. Understanding the relationship between olfactory-specific quality of life, objective olfactory loss, and patient factors in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(7):734-740. doi:10.1002/alr.21940
Beswick DM, Humphries SM, Miller JE, et al. Objective and patient-based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy. Int Forum Allergy Rhinol. 2022;12(11):1435-1438. doi:10.1002/alr.23016
Humphries SM, Centeno JP, Notary AM, et al. Volumetric assessment of paranasal sinus opacification on computed tomography can be automated using a convolutional neural network. Int Forum Allergy Rhinol. 2020;10(11):1218-1225. doi:10.1002/alr.22588